D
Altimmune, Inc. ALT
$5.61 -$0.36-6.03%
Recommendation
Sell
Prev Close
$5.97
Volume
2,530,000
Avg Vol (90D)
3,167,250
Market Cap
$459.77M
Dividend & Yield
--
52-Week Range
$5.14 - $11.16
P/E (TTM)
--
EPS (TTM)
-$1.34
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Altimmune (ALT, $5.97) Aroon Indicator entered a Downtrend on March 17, 2025.
3/18/2025 - Tickeron - Technical Analysis
Altimmune (ALT, $5.97) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 17, 2025
3/18/2025 - Tickeron - Technical Analysis
Altimmune (ALT, $5.97) Stochastic Oscillator left the oversold zone on March 17, 2025
3/18/2025 - Tickeron - Technical Analysis
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
3/17/2025 - Seeking Alpha: Editor's Picks
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
3/17/2025 - Seeking Alpha - Long Ideas
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
3/17/2025 - SeekingAlpha
Altimmune call volume above normal and directionally bullish
3/17/2025 - TipRanks Financial Blog
Altimmune call volume above normal and directionally bullish
3/17/2025 - The Fly
William Blair Reaffirms "Market Perform" Rating for Altimmune (NASDAQ:ALT)
3/16/2025 - MarketBeat
Altimmune Sees Unusually High Options Volume (NASDAQ:ALT)
3/15/2025 - MarketBeat
Insider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Purchases 10,000 Shares of Stock
3/15/2025 - MarketBeat
Insider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Acquires 10,000 Shares of Stock
3/15/2025 - Ticker Report
Insider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Acquires 10,000 Shares of Stock
3/15/2025 - MarketBeat
Altimmune (ALT, $5.92) Aroon Indicator entered a Downtrend on March 14, 2025.
3/15/2025 - Tickeron - Technical Analysis
Noteworthy Friday Option Activity: DXC, ALT, MSFT
3/14/2025 - Stock Options Channel
Altimmune rises as buyout rumors follow R&D updates
3/14/2025 - Seeking Alpha - Healthcare
Altimmune rises as buyout rumors follow R&D updates
3/14/2025 - SeekingAlpha.com: All News
Altimmune soars amid takeover speculation
3/14/2025 - Seeking Alpha - Healthcare
Altimmune soars amid takeover speculation
3/14/2025 - SeekingAlpha.com: All News
Altimmune call volume above normal and directionally bullish
3/14/2025 - TipRanks Financial Blog
Altimmune call volume above normal and directionally bullish
3/14/2025 - The Fly
Evercore bullish on Altimmune, likes drug move into alcohol related disease
3/14/2025 - TipRanks Financial Blog
Evercore bullish on Altimmune, likes drug move into alcohol related disease
3/14/2025 - The Fly
Stifel Nicolaus Keeps Their Buy Rating on Altimmune (ALT)
3/14/2025 - TipRanks Financial Blog
Altimmune (ALT, $5.2) Aroon Indicator entered a Downtrend on March 13, 2025.
3/14/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$20.00K
EBITDA (TTM)
-$102.93M
EBIT (TTM)
-$103.17M
Net Income (TTM)
-$95.06M
Balance Sheet
Total Assets (Q)
$139.31M
Total Debt (Q)
$1.68M
Total Liabilities (Q)
$15.80M
Book Value Per Share (Q)
$1.71
Cash Flow
Cash from Operations (TTM)
-$79.85M
Cash from Investing (TTM)
-$28.39M
Cash from Financing (TTM)
$10.04M
Net Change in Cash (TTM)
-$98.19M
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
2.01
7-Day Total Return
0.72%
30-Day Total Return
-12.89%
60-Day Total Return
-33.21%
90-Day Total Return
-17.38%
Year to Date Total Return
-21.10%
1-Year Total Return
-38.22%
2-Year Total Return
-48.63%
3-Year Total Return
-22.19%
5-Year Total Return
98.94%
52-week Low
Mar 13, 2025 - $5.14
52-week High
Nov 13, 2024 - $11.16
Valuation
Market Cap
$459.77M - Small Cap
Enterprise Value
$329.56M
Price/Sales (TTM)
29,850.00
Price/Book (Q)
3.50
Dividends and Shares
Shares Outstanding
71.26M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
altimmune.com
Phone Number
240 654 1450
Address
910 Clopper Road
Gaithersburg, MD 20878
Country
United States
Year Founded
1997
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon... more
NASDAQ 03/18/2025 4:00PM Eastern Quotes delayed
Weiss Ratings